Tian Zhang

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 37

Top Topics

Advanced Non Small Cell Lung Cancer

Radical Prostatectomy

Renal Cell Carcinoma

Top Venues

Journal for immunotherapy of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Prostate cancer and prostatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Casey Timmerman, Isabel Naraine, Tian Zhang
Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. The oncologist 29 (8) (2024)
Tian Zhang, Alan Tan, Amishi Y Shah, Gopa Iyer, Valerie Morris, Sébastien Michaud, Srikala S Sridhar
Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma. The oncologist (2024)
Pedro C Barata, Catherine M Tangen, Melissa Plets, Ian M Thompson, Vivek Narayan, Daniel J George, Daniel Y C Heng, Brian M Shuch, Mark N Stein, Shuchi Gulati, Maria Tretiakova, Abhishek Tripathi, Georg Arnold Bjarnason, Peter Humphrey, Adebowale Adeniran, Ulka N Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Primo N Lara, Seth P Lerner, Naomi B Haas, Sumanta Kumar Pal
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Casey Timmerman, Isabel Naraine, Tian Zhang
Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. The oncologist (2024)
Casey Timmerman, Isabel Naraine, Tian Zhang
Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. The oncologist 29 (8) (2024)
Ryan E Fecteau, Bridget F Koontz, Karen E Hoffman, Susan Halabi, Lauren E Howard, Monika Anand, Daniel J George, Tian Zhang, William R Berry, W Robert Lee, Michael R Harrison, Paul G Corn, Andrew J Armstrong
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Prostate cancer and prostatic diseases (2024)
Matthew T Campbell, Tian Zhang
Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure? Cancers 15 (21) (2023)
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer, Ravi A Madan, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Ray Li, Kam Chan, Helen Cho, Megan Kaneda, I-Ming Wang, Jenny Zheng, Szu-Yu Tang, Robert Hollingsworth, Kenneth A Kern, Daniel P Petrylak
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer 11 (3) (2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for immunotherapy of cancer 11 (5) (2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for immunotherapy of cancer 11 (5) (2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for immunotherapy of cancer 11 (5) (2023)
W Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, Hikmat A Al-Ahmadie, Hamid Emamekhoo, Ralph J Hauke, Alexander V Louie, Matthew I Milowsky, Ana M Molina, Tracy L Rose, Shankar Siva, Nicholas G Zaorsky, Tian Zhang, Rubina Qamar, Terry M Kungel, Bryan Lewis, Eric A Singer
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Yu-Wei Chen, Matthew D Tucker, Landon C Brown, Hesham A Yasin, Kristin K Ancell, Andrew J Armstrong, Kathryn E Beckermann, Nancy B Davis, Michael R Harrison, Elizabeth G Kaiser, Renee K McAlister, Kerry R Schaffer, Deborah E Wallace, Daniel J George, W Kimryn Rathmell, Brian I Rini, Tian Zhang
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers 14 (15) (2022)
Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak, David S Hong
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for immunotherapy of cancer 10 (2) (2022)
Landon C Brown, Susan Halabi, Jason A Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren E Howard, Jiaoti Huang, Monika Anand, Catrin Davies, Prekshaben Patel, Janet Staats, Kent J Weinhold, Michael R Harrison, Tian Zhang, Daniel J George, Andrew J Armstrong
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate cancer and prostatic diseases 25 (4) (2022)
Landon C Brown, Kunal Desai, Wei Wei, Emily N Kinsey, Chester Kao, Daniel J George, Brian I Rini, Moshe C Ornstein, Tian Zhang
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for immunotherapy of cancer 9 (9) (2022)
Hannah E Dzimitrowicz, Lauren E Wilson, Bradford E Jackson, Lisa P Spees, Christopher D Baggett, Melissa A Greiner, Deborah R Kaye, Tian Zhang, Daniel J George, Charles D Scales, Jessica E Pritchard, Michael S Leapman, Cary P Gross, Michaela A Dinan, Stephanie B Wheeler
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO oncology practice (2022)
Tian Zhang, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, Katherine Franz, Hannah Berg, Georgia S Karachaliou, Olga G James, Lauren Howard, Susan Halabi, Michael R Harrison, Andrew J Armstrong, Daniel J George
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. The Prostate 82 (7) (2022)
Michael R Harrison, Paul G Davis, Michel G Khouri, David Christopher Bartlett, Rajan T Gupta, Andrew J Armstrong, Megan A McNamara, Tian Zhang, Monika Anand, Kelly Onyenwoke, Sara Edwardson, Danielle Craig, Meghan Michalski, Yuan Wu, Taofik Oyekunle, Brian Coyne, Aubrie Coburn, Lee W Jones, Daniel J George
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). Prostate cancer and prostatic diseases 25 (1) (2022)
Tracy L Rose, Michael R Harrison, Allision M Deal, Sundhar Ramalingam, Young E Whang, Blaine Brower, Mary Dunn, Chelsea K Osterman, Hillary M Heiling, Marc A Bjurlin, Angela B Smith, Matthew E Nielsen, Hung-Jui Tan, Eric Wallen, Michael E Woods, Daniel J George, Tian Zhang, Anthony Drier, William Y Kim, Matthew I Milowsky
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (28) (2021)
Tian Zhang, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, Chandra Rao, Monika Anand, Taofik Oyekunle, Patrick Healy, Megan A McNamara, Kathryn Ware, Jason A Somarelli, Daniel J George, Andrew J Armstrong
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker research 9 (1) (2021)
Tian Zhang, Daniel J George
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. Nature medicine 27 (4) (2021)
Landon C Brown, Kunal B Desai, Tian Zhang, Moshe C Ornstein
The Immunotherapy Landscape in Renal Cell Carcinoma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (6) (2021)
Landon C Brown, Matthew D Tucker, Ramy Sedhom, Eric B Schwartz, Jason Zhu, Chester Kao, Matthew Kyle Labriola, Rajan T Gupta, Daniele Marin, Yuan Wu, Santosh Gupta, Tian Zhang, Michael R Harrison, Daniel J George, Ajjai Alva, Emmanuel S Antonarakis, Andrew J Armstrong
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for immunotherapy of cancer 9 (3) (2021)
Joyce K Hwang, Tian Zhang, Andrew Z Wang, Zihai Li
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. Journal of hematology & oncology 14 (1) (2021)
Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas P Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer medicine 10 (7) (2021)
Lisa P Spees, Stephanie B Wheeler, Bradford E Jackson, Christopher D Baggett, Lauren E Wilson, Melissa A Greiner, Deborah R Kaye, Tian Zhang, Daniel George, Charles D Scales, Jessica E Pritchard, Michael Leapman, Cary P Gross, Michaela A Dinan
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer medicine 10 (19) (2021)
Matthew Kyle Labriola, Jason Zhu, Rajan T Gupta, Shannon McCall, Jennifer Jackson, Eric F Kong, James R White, Gustavo Cerqueira, Kelly Gerding, John K Simmons, Daniel George, Tian Zhang
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. Journal for immunotherapy of cancer 8 (1) (2021)
Daniel J George, Susan Halabi, Elisabeth I Heath, A Oliver Sartor, Guru P Sonpavde, Devika Das, Rhonda L Bitting, William Berry, Patrick Healy, Monika Anand, Carol Winters, Colleen Riggan, Julie Kephart, Rhonda Wilder, Kellie Shobe, Julia Rasmussen, Matthew I Milowsky, Mark T Fleming, James Bearden, Michael Goodman, Tian Zhang, Michael R Harrison, Megan McNamara, Dadong Zhang, Bonnie L LaCroix, Rick A Kittles, Brendon M Patierno, Alexander B Sibley, Steven R Patierno, Kouros Owzar, Terry Hyslop, Jennifer A Freedman, Andrew J Armstrong
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer 127 (16) (2021)
Kunal B Desai, Landon C Brown, Wei Wei, Matthew D Tucker, Chester Kao, Emily Kinsey, Brian Rini, Kathryn E Beckermann, Tian Zhang, Moshe C Ornstein
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted oncology 16 (5) (2021)
Matthew D Tucker, Landon C Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N Kinsey, Kristin K Ancell, Kathryn E Beckermann, Nancy B Davis, Renee McAlister, Kerry Schaffer, Andrew J Armstrong, Michael R Harrison, Daniel J George, W Kimryn Rathmell, Brian I Rini, Tian Zhang
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker research 9 (1) (2021)
Stephanie B Wheeler, Lisa P Spees, Bradford E Jackson, Christopher D Baggett, Lauren E Wilson, Melissa A Greiner, Deborah R Kaye, Tian Zhang, Daniel J George, Charles D Scales, Jessica E Pritchard, Michaela A Dinan
Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. JCO oncology practice 17 (12) (2021)
Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R Harrison, Christopher J Hoimes, Daniel J George, Andrew J Armstrong, Tian Zhang
Novel therapies are changing treatment paradigms in metastatic prostate cancer. Journal of hematology & oncology 13 (1) (2020)
Andrew J Armstrong, Jun Luo, David M Nanus, Paraskevi Giannakakou, Russell Z Szmulewitz, Daniel Costin Danila, Patrick Healy, Monika Anand, William R Berry, Tian Zhang, Michael R Harrison, Changxue Lu, Yan Chen, Giuseppe Galletti, Joseph D Schonhoft, Howard I Scher, Richard Wenstrup, Scott T Tagawa, Emmanuel S Antonarakis, Daniel J George, Susan Halabi
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology 4 (2020)
Tian Zhang, Michael R Harrison, Peter H O'Donnell, Ajjai S Alva, Noah M Hahn, Leonard J Appleman, Jeremy Cetnar, John M Burke, Mark T Fleming, Matthew I Milowsky, Amir Mortazavi, Neal Shore, Guru P Sonpavde, Emmett V Schmidt, Bojena Bitman, Veerendra Munugalavadla, Raquel Izumi, Priti Patel, Janet Staats, Cliburn Chan, Kent J Weinhold, Daniel J George
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer 126 (20) (2020)
Jason Zhu, Andrew J Armstrong, Terence W Friedlander, Won Kim, Sumanta K Pal, Daniel J George, Tian Zhang
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. Journal for immunotherapy of cancer 6 (1) (2018)
Subha Bakthavatsalam, Mark L Sleeper, Azim Dharani, Daniel J George, Tian Zhang, Katherine J Franz
Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angewandte Chemie (International ed. in English) 57 (39) (2018)